Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

[1]  Shuhong Li,et al.  A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. , 2022, Blood.

[2]  Zhaoming Li,et al.  Autologous nanobody-derived fratricide-resistant CD7-CAR T cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Jiali Cheng,et al.  T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape , 2022, Signal Transduction and Targeted Therapy.

[4]  Ansuman T. Satpathy,et al.  Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL. , 2021, Cancer discovery.

[5]  D. Chihara,et al.  Targeted based therapy in nodal T-cell lymphomas , 2021, Leukemia.

[6]  Weiqi Wang,et al.  Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[7]  Jun Zhao,et al.  Nanobody: a promising toolkit for molecular imaging and disease therapy , 2021, EJNMMI Research.

[8]  G. Przybylski,et al.  Novel targeted therapies of T cell lymphomas , 2020, Journal of Hematology & Oncology.

[9]  H. Ploegh,et al.  Nanobodies in cancer. , 2020, Seminars in immunology.

[10]  Zhiqiang Wu,et al.  Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. , 2020, Blood.

[11]  W. Chan,et al.  Peripheral T cell lymphomas: from the bench to the clinic , 2020, Nature Reviews Cancer.

[12]  H. Ploegh,et al.  Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments , 2020, Cancer Immunology Research.

[13]  J. Tavernier,et al.  Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly , 2020, International journal of molecular sciences.

[14]  Meijuan Huang,et al.  Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56 , 2019, Nature Communications.

[15]  Zhiqiang Wu,et al.  Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation , 2019, Journal of Hematology & Oncology.

[16]  R. Hynes,et al.  Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice , 2019, Proceedings of the National Academy of Sciences.

[17]  P. Dreger.  Comment to “The outcome of peripheral T-cell lymphoma patients failing first-line therapy” , 2019, Haematologica.

[18]  U. Rix,et al.  An immunoproteomic approach to characterize the CAR interactome and signalosome , 2019, Science Signaling.

[19]  J-Pablo Salvador,et al.  Nanobody: outstanding features for diagnostic and therapeutic applications , 2019, Analytical and Bioanalytical Chemistry.

[20]  B. Lei,et al.  A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma , 2018, Journal of Hematology & Oncology.

[21]  Christopher A. Miller,et al.  An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies , 2018, Leukemia.

[22]  N. Pemmaraju.  Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond , 2017, Current Hematologic Malignancy Reports.

[23]  Hao Liu,et al.  Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. , 2017, The Journal of clinical investigation.

[24]  T. Waldmann,et al.  Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T‐cell malignancies , 2017, American journal of hematology.

[25]  Ciaran M. Lee,et al.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. , 2017, Blood.

[26]  A. Kuhn,et al.  The Transmembrane Morphogenesis Protein gp1 of Filamentous Phages Contains Walker A and Walker B Motifs Essential for Phage Assembly , 2017, Viruses.

[27]  Michael L. Wang,et al.  The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma , 2017, British journal of haematology.

[28]  H. Tony,et al.  Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. , 2017, Blood.

[29]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[30]  S. Grupp,et al.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. , 2016, The Journal of clinical investigation.

[31]  Yang Liu,et al.  Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial , 2016, Clinical Cancer Research.

[32]  Xu Zhang,et al.  Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy , 2016, Journal of Virology.

[33]  M. Cazzola.  Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. , 2016, Blood.

[34]  Y. Chen,et al.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells , 2016, Cancer Immunology Research.

[35]  Yupo Ma,et al.  Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells , 2016, Leukemia.

[36]  M. Brenner,et al.  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. , 2015, Blood.

[37]  K. Savage,et al.  Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Oliveira,et al.  Nanobody-based cancer therapy of solid tumors. , 2015, Nanomedicine.

[39]  Yang Liu,et al.  Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. , 2014, Clinical immunology.

[40]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[41]  M. Jerkeman,et al.  Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. , 2014, Blood.

[42]  H. Wajant,et al.  ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade , 2014, mAbs.

[43]  J. Cortes,et al.  CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis , 2014, Leukemia & lymphoma.

[44]  D. Weisenburger,et al.  Differences in incidence and trends of haematological malignancies in Japan and the United States , 2013, British journal of haematology.

[45]  S. Magez,et al.  Novel therapy based on camelid nanobodies. , 2013, Therapeutic delivery.

[46]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[47]  M. Shokrgozar,et al.  Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. , 2013, Cancer letters.

[48]  R. Gascoyne,et al.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[50]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma , 2012, Clinical Cancer Research.

[51]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Matthew Greenwood,et al.  Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Dhodapkar,et al.  Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. , 2011, Clinical immunology.

[54]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[56]  H. Heslop,et al.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.

[57]  Mark Ende,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[58]  S. Pileri,et al.  Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Andrew Gibson,et al.  AP2 Adaptor Complex-Dependent Internalization of CD5: Differential Regulation in T and B Cells1 , 2002, The Journal of Immunology.

[60]  W. Leonard.  Cytokines and immunodeficiency diseases , 2001, Nature Reviews Immunology.

[61]  C Cambillau,et al.  Thermal unfolding of a llama antibody fragment: a two-state reversible process. , 2001, Biochemistry.

[62]  B. de Geus,et al.  Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. , 2000, Molecular immunology.

[63]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[64]  I. Pastan,et al.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  L. Wyns,et al.  Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies , 1997, FEBS letters.

[66]  G. Studnicka,et al.  Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. , 1994, Protein engineering.

[67]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[68]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Harris,et al.  Introduction to a review series: the 2016 revision of the WHO classi fi cation of tumors of hematopoietic and lymphoid tissues , 2016 .

[70]  F. Stirpe,et al.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. , 1995, Blood.